Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in HIV-Infected Patients With Relapsed/Refractory B-Cell Malignancies
NCT02109224Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibrutinib in B-cell non-Hodgkin lymphoma and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoints: Incidence of toxicities at 30 days and Maximum Tolerated Dose at 28 days. Started Sep 2014; status: terminated.
02
Drugs
ibrutinib
03
Conditions
B-cell non-Hodgkin lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02109224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109224.